Eris Lifesciences FY26 results: ₹7.21 interim dividend

Key announcement from the board

Eris Lifesciences Ltd said its board approved and took on record the audited standalone and consolidated financial results for the quarter and year ended March 31, 2026. The company also said the audit reports carried unmodified opinions. Alongside the results, the board declared an interim dividend for FY26-27. The update matters for investors because it combines a dividend action with a sharp divergence between standalone March-quarter profitability and the consolidated profit figures reported elsewhere in the disclosures.

Interim dividend: amount, record date, and timeline

Eris Lifesciences declared an interim dividend of ₹7.21 per share (721%) for FY26-27. The record date was set as May 29, 2026. The company indicated the dividend would be paid on or before June 19, 2026. For shareholders, these dates determine eligibility and expected cash-flow timing.

Standalone Q4 FY26 snapshot vs Q3 FY26

A standalone quarter-on-quarter comparison provided in the data shows pressure on operating performance in Q4 FY26 versus Q3 FY26. Revenue was listed at ₹304.28 crore, down 10.6% sequentially. Expenditure was ₹337.05 crore, up 4.7% quarter-on-quarter. Net profit was -₹8.60 crore, a decline of 378.3%, and operating profit margin (OPM) was 7.85%, down 12.03 percentage points. These figures frame the March quarter as a difficult standalone period on both revenue momentum and cost control.

What the standalone quarterly table shows (Mar 2025 to Mar 2026)

The standalone quarterly table (all figures in ₹ crore) shows a steady decline in net sales from September 2025 to March 2026. Net sales moved from ₹650.50 crore in Sep 2025 to ₹315.29 crore in Dec 2025 and ₹277.31 crore in Mar 2026. Over the same span, operating profit fell from ₹296.88 crore (Sep 2025) to ₹77.35 crore (Dec 2025) and ₹21.78 crore (Mar 2026). Profit after tax (PAT) also turned negative in Mar 2026 at -₹8.60 crore after being ₹3.09 crore in Dec 2025.

Consolidated profitability: Reuters-style figures in the data

Separate earnings figures included in the provided text show a very different picture at the consolidated level for the fourth quarter and full year ended March 31, 2026. For the fourth quarter, revenue was ₹758.79 crore compared with ₹713.25 crore a year ago (originally stated as INR 7,587.9 million vs INR 7,132.5 million). Net income was ₹281.61 crore compared with ₹93.84 crore a year ago (INR 2,816.1 million vs INR 938.4 million). For the full year, revenue was ₹3,137.17 crore compared with ₹2,912.00 crore a year ago (INR 31,371.7 million vs INR 29,120 million). Full-year net income was ₹619.52 crore compared with ₹351.84 crore a year ago (INR 6,195.2 million vs INR 3,518.4 million).

Earnings per share numbers mentioned

The same set of consolidated earnings figures included earnings per share (EPS) from continuing operations. Basic EPS for the fourth quarter was 20.6 versus 6.9 a year ago, and diluted EPS was 20.57 versus 6.89. For the full year, basic EPS was 45.33 versus 25.85, while diluted EPS was 45.26 versus 25.81. These EPS numbers are presented alongside the consolidated revenue and net income figures and indicate a strong year-on-year improvement in the consolidated metrics cited.

Stock price context cited in the data

The text also captured a market snapshot for Eris Lifesciences. The share price was listed at ₹1,448.40, up ₹17.80 (1.24%). The timestamp shown was “NSE: 19 Jun 4:00 PM”. While this is only a point-in-time quote, it provides a reference for where the stock was trading around the period referenced.

Earlier FY26 quarterly datapoints referenced

The provided text also included select quarterly commentary for FY26. For Q1 FY26, Eris Lifesciences reported revenue of ₹773 crore with a 7.4% change, EBIDTA of ₹277 crore, and margin expansion of 106 bps year-on-year from 34.7% to 35.8%. It also noted a 20% year-on-year reduction in interest expense, from ₹60 crore in Q1 FY25 to ₹49 crore in Q1 FY26, and Q1 PAT of ₹125 crore (up 41% year-on-year). For Q2 FY26, the data showed total income of ₹795.22 crore, total expenses of ₹622.83 crore, profit before tax of ₹172.39 crore, tax of ₹38.20 crore, profit after tax of ₹134.47 crore, and EPS of ₹8.81.

Why the mixed standalone and consolidated picture matters

The standalone March-quarter table shows a sharp drop in operating profit and a negative PAT in Mar 2026, with an exceptional item of -₹14.67 crore recorded in Dec 2025 and none shown in Mar 2026. In contrast, the consolidated figures presented in the same dataset show a year-on-year jump in net income for the March quarter and for the full year. For investors, this gap highlights that standalone and consolidated performance can diverge depending on group structure, income streams, and how costs and financing play out across entities. The dividend declaration adds another data point for capital return, but it does not by itself resolve the question of why standalone profitability weakened in the March quarter.

Conclusion

Eris Lifesciences’ FY26 update combined audited results, an unmodified audit opinion, and an interim dividend of ₹7.21 per share with a record date of May 29, 2026. The standalone March-quarter table showed lower sales and a PAT loss of ₹8.60 crore, while the consolidated figures cited showed higher year-on-year net income for both the quarter and the full year. Investors will likely track follow-up disclosures for additional clarity across standalone and consolidated trends, along with confirmation of dividend payment on or before June 19, 2026.